TY  -  
T1  - Hydroxysteroid 17-beta dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease 
SN  -  /  
UR  - http://hdl.handle.net/10138/325971 
T3  -  
A1  - Luukkonen, Panu K.; Tukiainen, Taru; Juuti, Anne; Sammalkorpi, Henna; Haridas, P. A. Nidhina; Niemelä, Onni; Arola, Johanna; Orho-Melander, Marju; Hakkarainen, Antti; Kovanen, Petri T.; Dwivedi, Om; Groop, Leif; Hodson, Leanne; Gastaldelli, Amalia; Hyötyläinen, Tuulia; Oresic, Matej; Yki-Järvinen, Hannele 
A2  -  
PB  -  
Y1  - 2020 
LA  - eng 
AB  - Carriers of the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene variant (rs72613567:TA) have a reduced risk of NASH and cirrhosis but not steatosis. We determined its effect on liver histology, lipidome, and transcriptome using ultra performance liquid chromatography-mass spectrometry and RNA-seq. In carriers and noncarriers of the gene variant, we also measured pathways of hepatic fatty acids (de novo lipogenesis [ONLI and adipose tissue lipolysis [ATL] using (H2O)-H-2 and H-2-glycerol)... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - DE-NOVO LIPOGENESIS; INSULIN-RESISTANCE; PHOSPHATIDYLCHOLINE; CHOLINE; GLUCOSE; STEATOHEPATITIS; INDIVIDUALS; HOMEOSTASIS; NUTRIENT; PACKAGE; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -